Dinesh V. Patel, PhD

CEO & President of Protagonist Therapeutics. 38 years of executive, entrepreneural, and scientific experience spanning big pharma & biotechs, and loving it!

[Dinesh V. Patel, PhD @ProtagonistCEO]

@CNBCFastMoney @ProtagonistTx It was such an honor to be on Melissa Lee’s CNBC fast money show today. Sincere thanks to team @ProtagonistTx for creating this level of credibility and visibility. We just keep moving forward relentlessly. Cheers!

[Dinesh V. Patel, PhD @ProtagonistCEO]

Rusfertide, currently under a priority NDA review at FDA, is the outcome of a research program initiated at @ProtagonistTx in 2012. By opting-out of further co-development and co-commercialization, we place the company in an even stronger financial position while benefiting patients, our shareholders, and @TakedaPharma. Eagerly awaiting the potential approval in third quarter. Cheers!

[Protagonist Therapeutics @ProtagonistTx]

Protagonist has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under our worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide. Rusfertide is now under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera (PV).

Read more: https://t.co/mAWPAFZlw4

[Dinesh V. Patel, PhD @ProtagonistCEO]

Slow and steady does it. Humble beginnings from 2008 to now, but we are just not done yet. Repeat performance is the real charm. Cheers!

[Protagonist Therapeutics @ProtagonistTx]

What a week for all of us at Protagonist! After celebrating the FDA Approval of ICOTYDE, we are thrilled to be recognized on the Nasdaq Tower in Times Square as a Fast 500 company. Ranking among the fastest-growing innovative companies in North America is a powerful validation of our innovation platform. To our customers, partners, and every member of the Protagonist family: This moment belongs to you. We’re just getting started. Looking forward to what's yet to come.

#PTGX #NASDAQ #BayAreaFast500 #Biotech #Innovation

[Vivek Patel @VDP83]

Congrats dad (@ProtagonistCEO)!

I'm *so* proud of what you and the @ProtagonistTx team have achieved. 13yrs end-to-end from R&D to full FDA approval for a new drug. It's inspiring.

[Dinesh V. Patel, PhD @ProtagonistCEO]

Proud moment for Protagonist Therapeutics: today’s FDA approval of ICOTYDE marks 13 years of scientific dedication and operational excellence.

A testament to our peptide platform and collaboration with Johnson & Johnson. Grateful to all who made this possible.

[Protagonist Therapeutics @ProtagonistTx]

Today the FDA approved ICOTYDE™ (icotrokinra), the first targeted oral peptide option for first-line systemic treatment of plaque psoriasis.

This milestone reflects the power of our science and platform. Thank you to the PTGX team, Johnson & Johnson, investigators and patients who made it possible.

Read more: https://t.co/0TNwYudXbD

[Dinesh V. Patel, PhD @ProtagonistCEO]

The FDA’s decision to grant Priority Review for rusfertide marks an important step in our decade-plus long and ongoing journey. Big Congrats and sincere thanks to the @ProtagonistTx team for your persistence, scientific rigor, and commitment. We are pleased to be working with Takeda on this potential first-in-class therapy for patients with polycythemia vera.

[Protagonist Therapeutics @ProtagonistTx]

Today, Protagonist and Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV).

Read more details in our latest press release: https://t.co/NTylXEIowQ

[Dinesh V. Patel, PhD @ProtagonistCEO]

Protagonist is off to a strong start in 2026.

Together with Takeda, we’ve submitted an NDA to the FDA for rusfertide, a first-in-class investigational hepcidin mimetic for PV. Grateful to the patients, investigators, and teams who made this possible.

Looking forward to JPM and sharing more updates ahead!

[Protagonist Therapeutics @ProtagonistTx]

Takeda and Protagonist Therapeutics have announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV).

Read more in our latest press release: https://t.co/jQNSUBv95Y

[Protagonist Therapeutics @ProtagonistTx]

Happy holidays from Protagonist Therapeutics! Warmest wishes to you and yours this holiday season ❄️

[Protagonist Therapeutics @ProtagonistTx]

It’s #WorldPsoriasisDay, and this year's theme aims to put a spotlight on Psoriatic Disease and Comorbidities. Psoriasis is a journey of visible and invisible challenges that not only impacts the skin, but also overall health and well-being.

At Protagonist Therapeutics, we’re proud to join @NPF and the global psoriasis community to raise awareness, advance research, and work toward a future with better care for the 125 million people around the globe living with psoriasis.

[Protagonist Therapeutics @ProtagonistTx]

Our EVP of Business Development, Carter King, will join a panel on 'Deal Stories – Wins, Misses, and What We'd Do Differently' tomorrow from 9:30-10:15 AM at #FierceBiotechWeek.

More details here: https://t.co/CqyPerEH7F

[Protagonist Therapeutics @ProtagonistTx]

For more than 20 years, @CALifesciences has celebrated individuals and organizations who are making exceptional contributions to the life sciences industry.

There is one more day for the Pantheon 2025 Awards voting, and our Protagonist team needs your help to win!
Vote for us in the Biopharma Product of the year category today: https://t.co/e7iD7Ymgdz

[Dinesh V. Patel, PhD @ProtagonistCEO]

We are honored and happy with such a nomination, which in itself is a great recognition.

Congrats to team @ProtagonistTx and to all the well deserving nominees.

[Protagonist Therapeutics @ProtagonistTx]

We are pleased to see Protagonist be named a @Citeline 2025 #ScripAwards finalist for “Clinical Advance of the Year” in recognition of the highly positive outcome of the Phase III VERIFY study of rusfertide in polycythemia vera (PV).

We are honored to be in the company of other innovative finalists working to advance healthcare.

See the shortlist here: https://t.co/OFmI6phm4w

[Dinesh V. Patel, PhD @ProtagonistCEO]

We’re pleased to see new data at #EADV2025, from icotrokinra’s Phase 3 durability and head-to-head superiority vs. Sotyktu to PN-881’s potent dual IL-17A&F inhibition and preclinical efficacy. These results once again reflect the strength of our oral peptide platform.

[Protagonist Therapeutics @ProtagonistTx]

From platform to pipeline to patients. Presentations this week at #EADV2025 will demonstrate the potential of our peptide therapeutic discovery and development platform to redefine standards in psoriasis care.

Read more: https://t.co/vJAJZcAOHN

[Dinesh V. Patel, PhD @ProtagonistCEO]

@ProtagonistTx Nice to see ICO scoring well both in Derm and IBD indications.

[Dinesh V. Patel, PhD @ProtagonistCEO]

The EMA filing for #icotrokinra marks another major step forward toward bringing this first-in-class investigational therapy with the convenience of a once-daily tablet to patients with psoriasis. We at Protagonist are proud of what our partnership with @JNJNews represents for the future of peptide therapeutics.

[Protagonist Therapeutics @ProtagonistTx]

Today, we announced that Johnson & Johnson (@JNJNews) has submitted a Marketing Authorization Application to the European Medicines Agency for icotrokinra, a first‑in‑class investigational oral peptide co-discovered by Protagonist and J&J scientists for adults and adolescents with moderate‑to‑severe plaque #psoriasis.

Read more:
https://t.co/n20N8y09Be

[Dinesh V. Patel, PhD @ProtagonistCEO]

Another win for @ProtagonistTx: rusfertide receives FDA Breakthrough Therapy designation for erythrocytosis treatment in polycythemia vera. Grateful to our team & partners.

NDA submission planned by year-end.

https://t.co/ljKRYjTFGY

[Dinesh V. Patel, PhD @ProtagonistCEO]

A landmark moment for #PTGX: the NDA for oral #icotrokinra has been submitted to the FDA. This is the first NDA resulting from our peptide discovery & development platform in collab with our partners at @JNJNews. Congrats & thanks to everyone on the PTGX and J&J teams. Cheers!

[Protagonist Therapeutics @ProtagonistTx]

News: Protagonist is pleased to announce the submission of a New Drug Application for icotrokinra, the first- and best-in-class oral IL-23R blocker for plaque #psoriasis. Four pivotal Phase 3 ICONIC studies back its potential to transform care and expand across IL-23–mediated diseases.

Read more: https://t.co/4nSQlIP5fl

[Dinesh V. Patel, PhD @ProtagonistCEO]

Back to basics with solid ‘oral peptide’ differentiation in obesity, and with two NDA filings sometime in 2025 in rear view mirror - Icotrokinra with @JNJ and Rusfertide with @TakedaOncology. Feels like a rejuvenating reincarnation!

[Protagonist Therapeutics @ProtagonistTx]

Today, we hosted a conference call and webcast on our oral obesity development candidate, PN-477.

IND-enabling studies are underway, with Phase I study initiation expected in the second quarter of 2026.

Read more: https://t.co/2EsOOPFIHX
Watch the webcast replay: https://t.co/EscUItp8WH